Geron Corporation Reports First Quarter 2024 Financial Results and Business Highlights
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies, today reported financial results and business highlights for the first quarter 2024.
- Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies, today reported financial results and business highlights for the first quarter 2024.
- Revenues for the first quarter of 2024 were $304,000, compared to $21,000 for the same period in 2023.
- As of March 31, 2024, we had 162 full-time employees, prior to the onboarding of our salesforce in April 2024.
- ET on Thursday, May 2, 2024, to discuss business updates and first quarter financial results.